AccUrine specializes in rapid, non-invasive diagnostic solutions using urine for early disease detection and monitoring. The company’s platform leverages advanced proteomic analysis, machine learning, and proprietary algorithms to decode immune system signals from urine samples, eliminating the need for blood draws and traditional lab infrastructure. AccUrine’s first product — a rapid at-home lateral flow test — distinguishes bacterial from viral infections to support informed treatment decisions and reduce unnecessary antibiotic use. By combining cutting-edge technology with accessible point-of-care diagnostics, AccUrine aims to transform how diseases are detected and managed worldwide, expanding its impact across healthcare settings.

